Iterum Therapeutics (Iterum Therapeutics) Quick Ratio : 1.89 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Iterum Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Iterum Therapeutics's quick ratio for the quarter that ended in Dec. 2023 was 1.89.

Iterum Therapeutics has a quick ratio of 1.89. It generally indicates good short-term financial strength.

The historical rank and industry rank for Iterum Therapeutics's Quick Ratio or its related term are showing as below:

ITRM' s Quick Ratio Range Over the Past 10 Years
Min: 0.32 Med: 6.17 Max: 7.61
Current: 1.89

During the past 8 years, Iterum Therapeutics's highest Quick Ratio was 7.61. The lowest was 0.32. And the median was 6.17.

ITRM's Quick Ratio is ranked worse than
66.3% of 1555 companies
in the Biotechnology industry
Industry Median: 3.53 vs ITRM: 1.89

Iterum Therapeutics Quick Ratio Historical Data

The historical data trend for Iterum Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iterum Therapeutics Quick Ratio Chart

Iterum Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Quick Ratio

Get a 7-Day Free Trial

0.32

0.51

6.43

6.89

1.89

Iterum Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Quick Ratio	Get a 7-Day Free Trial															6.89	6.96	4.40	2.35	1.89

Competitive Comparison of Iterum Therapeutics's Quick Ratio

For the Biotechnology subindustry, Iterum Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Iterum Therapeutics's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iterum Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Iterum Therapeutics's Quick Ratio falls into.

Iterum Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Iterum Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )	=	(Total Current Assets	-	Total Inventories)	/	Total Current Liabilities
	=	(25.596	-	0)	/	13.518
	=	1.89

Iterum Therapeutics's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )	=	(Total Current Assets	-	Total Inventories)	/	Total Current Liabilities
	=	(25.596	-	0)	/	13.518
	=	1.89

Iterum Therapeutics (NAS:ITRM) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.

Iterum Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Iterum Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Iterum Therapeutics (Iterum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iterum Therapeutics PLC (NAS:ITRM) » Definitions » Quick Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

Fitzwilliam Court, 1st Floor, Leeson Close, Dublin, IRL, 2

Website

https://www.iterumtx.com

Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of innovative treatments for drug-resistant bacterial infections.

Executives

Michael W. Dunne	officer: Chief Scientific Officer	DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Fishman Corey N.	director, officer: President & CEO	DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Sailaja Puttagunta	officer: Chief Medical Officer	C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Brenton Karl Ahrens	director	2765 SAND HILL ROAD, MENLO PARK CA 94025
Judith M. Matthews	officer: Chief Financial Officer	200 WEST MONROE ST., SUITE 1575, CHICAGO IL 60606
Beth Hecht	director	C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050
Alexander J Denner	10 percent owner	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Hawkeye Fund Lp	10 percent owner	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Catapult Fund Llc	10 percent owner	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Master Fund Ii Lp	10 percent owner	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Offshore Master Fund Lp	10 percent owner	C/O SARISSA CAPITAL MANAGEMENT, 660 STEAMBOAT ROAD 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Management Lp	10 percent owner	660 STEAMBOAT ROAD, GREENWICH CT 06830
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116